| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.2% | -94% | $86,381 | -$4,589,007 | 65,940 | -98% | T. Rowe Price Associates, Inc. | 31 Jan 2025 |
As of 30 Sep 2025, 1 institutional investors reported holding 400 shares of IGM Biosciences, Inc. - Common Stock, par value $0.01 per share (IGMS). This represents 0% of the company’s total 34,723,329 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 400 | $508 | -$17,871,878 | $1.27 | 1 |
| 2025 Q2 | 15,960,828 | $17,875,835 | -$2,104,203 | $1.12 | 66 |
| 2025 Q1 | 17,818,423 | $20,490,330 | -$7,787,129 | $1.15 | 78 |
| 2024 Q4 | 21,675,386 | $132,436,529 | -$11,514,545 | $6.11 | 81 |
| 2024 Q3 | 21,552,420 | $356,554,699 | -$28,739,002 | $16.54 | 71 |
| 2024 Q2 | 22,262,648 | $152,945,906 | -$7,041,309 | $6.87 | 81 |
| 2024 Q1 | 22,815,461 | $220,169,478 | +$9,914,449 | $9.65 | 85 |
| 2023 Q4 | 21,900,333 | $181,991,703 | -$4,914,007 | $8.31 | 71 |
| 2023 Q3 | 22,316,660 | $186,343,110 | +$4,167,543 | $8.35 | 78 |
| 2023 Q2 | 21,774,197 | $200,973,364 | +$34,080,625 | $9.23 | 77 |
| 2023 Q1 | 17,755,754 | $243,788,540 | -$3,024,155 | $13.74 | 72 |
| 2022 Q4 | 17,975,744 | $305,732,057 | +$887,493 | $17.01 | 77 |
| 2022 Q3 | 17,687,605 | $401,962,815 | -$8,390,420 | $22.74 | 89 |
| 2022 Q2 | 17,501,111 | $315,557,489 | -$24,172,148 | $18.03 | 88 |
| 2022 Q1 | 18,211,636 | $486,765,522 | +$12,666,928 | $26.73 | 89 |
| 2021 Q4 | 17,637,328 | $517,295,289 | +$7,327,988 | $29.33 | 83 |
| 2021 Q3 | 16,900,148 | $1,111,361,370 | +$22,065,266 | $65.76 | 106 |
| 2021 Q2 | 16,339,254 | $1,358,868,495 | -$129,503,572 | $83.20 | 104 |
| 2021 Q1 | 17,999,061 | $1,381,196,583 | +$59,991,954 | $76.69 | 108 |
| 2020 Q4 | 17,177,904 | $1,516,624,749 | +$223,584,985 | $88.29 | 105 |
| 2020 Q3 | 14,663,143 | $1,082,301,675 | +$47,917,604 | $73.81 | 90 |
| 2020 Q2 | 14,016,977 | $1,023,203,077 | +$55,812,836 | $73.00 | 80 |
| 2020 Q1 | 13,271,249 | $742,032,915 | +$66,544,263 | $56.15 | 61 |
| 2019 Q4 | 12,196,527 | $463,251,136 | +$92,385,435 | $38.16 | 50 |
| 2019 Q3 | 10,035,118 | $178,125,000 | +$178,125,000 | $17.75 | 33 |